About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Massachusetts | 361 Studies

Clinical Trials MelanomaMassachusetts

Melanoma Clinical Trials in Massachusetts

Find 361 clinical trials for melanoma near Massachusetts. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Massachusetts

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 321-340 of 361 trials

TerminatedStudy to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceThe main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV…NCT04410445·Scottsdale, Arizona and 211 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedPembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorThis research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer.NCT03239145·Boston, Massachusetts and 1 other

TerminatedPh I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor…NCT01400451·Los Angeles, California and 3 others

CompletedStudy Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in…NCT02315066·Los Angeles, California and 29 others

No longer availableExpanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaThe purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have…NCT02186249·Gilbert, Arizona and 65 others

CompletedMassage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic CancerRATIONALE: Massage therapy may help relieve symptoms associated with cancer.NCT00253708·Boston, Massachusetts

CompletedA Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaThis was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib…NCT01584648·Scottsdale, Arizona and 120 others

CompletedInterferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the GroinRATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Interferon alfa-2b may interfere with the growth of cancer cells.NCT00003444·Atlanta, Georgia and 22 others

CompletedVaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV MelanomaThe purpose of this study is to learn if a vaccine made from the patient's own tumor cells, then genetically modified to secrete granulocyte-macrophage colony-stimulating factor…NCT00258687·Boston, Massachusetts and 1 other

TerminatedTiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyTiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer.NCT04596033·Gilbert, Arizona and 7 others

CompletedMGD019 DART® Protein in Unresectable/Metastatic CancerThe purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.NCT03761017·Chicago, Illinois and 38 others

CompletedAn Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaThe purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in…NCT03068455·Tucson, Arizona and 123 others

Active not recruitingSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCThis is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single…NCT04140526·Springdale, Arkansas and 36 others

RecruitingProject: Every Child for Younger Patients With CancerThis study gathers health information for the Project: Every Child for younger patients with cancer.NCT02402244·Birmingham, Alabama and 278 others

RecruitingA Phase 1 of CTX-8371 in Patients With Advanced MalignanciesThis is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies.NCT06150664·Margate, Florida and 9 others

TerminatedCMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaCMP-001-010 is a Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) administered to participants with refractory unresectable or metastatic melanoma.NCT04698187·Phoenix, Arizona and 24 others

CompletedInvestigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212This was an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination.NCT01072175·Los Angeles, California and 14 others

Active not recruitingTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialThis phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced)…NCT04284774·Birmingham, Alabama and 171 others

Active not recruitingStudy Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabThis Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety…NCT04130516·Los Angeles, California and 9 others

TerminatedPROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsTo obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation…NCT03993379·Duarte, California and 26 others

PreviousPage 17 of 19Next

Other Conditions in Massachusetts

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma